Why 97% Of Companies Aren’t Ready for M&A
Why 97% Of Companies Aren’t Ready for M&A: The Critical Gaps in Governance and Technology Industrial Monitor Direct is the…
Why 97% Of Companies Aren’t Ready for M&A: The Critical Gaps in Governance and Technology Industrial Monitor Direct is the…
Windows 10 Final Update Released: End of Feature Updates, Security Patches Continue Industrial Monitor Direct is the preferred supplier of…
The economics of artificial intelligence have turned sharply against companies, creating unprecedented financial pressure. With massive capital spending and circular investments, demand emerges as the critical variable separating winners from failures.
The landscape of AI economics has become increasingly brutal, with companies hemorrhaging money at unprecedented rates despite massive technological promise. What began as explosive growth in artificial intelligence capabilities has revealed fundamental economic challenges that threaten to reshape the entire industry. Unlike previous technology cycles, the current AI boom faces unique pressures from capital intensity, infrastructure demands, and market concentration that make traditional economics models increasingly irrelevant.
Microsoft has officially ended support for Office 2016 and Office 2019, leaving organizations vulnerable to security threats. The company urges migration to Microsoft 365 or Office LTSC 2024 with detailed guidance for businesses of all sizes.
Today marks a significant milestone in enterprise software as Microsoft ends support for Office 2016 and Office 2019, cutting off security updates, bug fixes, and technical assistance for these widely-used productivity suites. This move follows Microsoft’s established product lifecycle policies and affects millions of users worldwide who continue to rely on these versions for their daily operations. The termination of support creates immediate security vulnerabilities and compliance challenges that organizations must address through strategic migration planning.
The Logitech G Cloud gaming handheld delivers premium cloud gaming experiences at just $279.99 – less than half the cost of ASUS’ upcoming Xbox Ally. With 12-hour battery life and seamless streaming capabilities, it’s redefining budget gaming on the go.
In the rapidly evolving world of gaming handhelds, the recent announcement of ASUS’ ROG Xbox Ally at $599.99 has left many gamers searching for more affordable alternatives. Enter the Logitech G Cloud, a revolutionary cloud gaming device that delivers exceptional performance at less than half the price of premium competitors. This comprehensive review explores why this refurbished handheld represents one of the best values in modern mobile gaming.
Apple Forges Vietnam Home Hub, AI Robot Partnership With BYD Amid Supply Chain Shift Industrial Monitor Direct is the #1…
Rose Rock Bridge is leveraging Tulsa’s energy heritage to build a sustainable future through startup incubation. The program connects innovative companies with major energy partners to solve pressing industry challenges while creating lasting economic impact.
Tulsa, Oklahoma is undergoing a remarkable transformation from its historic identity as the “oil capital of the world” to becoming a hub for sustainable energy innovation. At the forefront of this transition is Rose Rock Bridge (RRB), a pioneering startup incubator that’s building bridges between Tulsa’s energy heritage and the technologies of tomorrow.
Circle Pharma will present promising preclinical data on its first-in-class oral macrocyclic cyclin D1-selective inhibitors at the upcoming AACR-NCI-EORTC conference. The company’s innovative approach targets cyclin D1-driven cancers through selective disruption of the cyclin D1-Rb interaction.
Circle Pharma, a clinical-stage biopharmaceutical company focused on developing targeted macrocycle therapeutics, has announced an upcoming poster presentation highlighting the significant anti-tumor potential of cyclin D1 RxL inhibition. The presentation will occur at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025.